The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Introduction

• The pneumococcal vaccine market has witnessed robust growth in recent years.
• Projected growth from $8.47 billion in 2023 to $9.04 billion in 2024 at a CAGR of 6.7%.

Historic Growth Drivers

• Discovery of Streptococcus pneumoniae.
• Public health concern and early vaccination efforts.
• Healthcare advancements and vaccine policy changes.

Expected Growth in the Coming Years

• Forecasted growth to $11.36 billion in 2028 at a CAGR of 5.9%.
• Factors include evolving strains, research and development, and expanded vaccine access.

View More On The Pneumococcal Vaccine Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Major Trends in the Forecast Period

• Multivalent vaccine development.
• Targeted vaccination strategies.
• Education and awareness campaigns.

Rising Prevalence of Pneumococcal Contamination Drives Market Growth

• Pneumococcal contamination encompasses various infections caused by Streptococcus pneumoniae.
• The vaccine stimulates antibody production to combat these infections.
• Increasing prevalence drives market growth, with significant hospitalization rates reported.

Key Players in the Market

• Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., among others.
• Diverse range of companies contributing to vaccine development and distribution.

Breakthrough in Vaccine Development

• Merck & Co Inc. launched V116 vaccine targeting eight serotypes of Streptococcus pneumoniae.
• V116 demonstrates superior immunogenicity in adult populations.
• FDA designates V116 as a breakthrough therapy, currently in Phase 3 development.

GSK Expands Vaccine Portfolio

• GSK PLC’s acquisition of Affinivax, Inc. expands its vaccine offerings.
• Access to MAPS technologies and 24-valent pneumococcal vaccine candidate.

Market Segmentation

1. Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products.
2. Route of Administration: Intravenous, Intramuscular, Subcutaneous.
3. Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Others.
4. End User: Pediatrics, Adults.

Regional Insights

• North America led the market in 2023.
• Asia-Pacific poised for rapid growth in the forecast period.

Conclusion

• The pneumococcal vaccine market shows substantial growth potential driven by increasing contamination prevalence and innovative vaccine development.
• Collaboration among pharmaceutical companies and advancements in vaccine technology are key factors shaping the market’s trajectory.
• With a focus on targeted vaccination strategies and expansion in emerging markets, the future of pneumococcal vaccine market appears promising.

Request A Sample Of The Global Pneumococcal Vaccine Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp